Targeted biologic agents and modern cell-based antibody assays have revolutionized clinical neuroimmunology worldwide. Today, clinicians managing central nervous system inflammatory disorders encounter expanding questions regarding optimal treatment duration. Specifically, tailoring NMOSD and MOGAD immunotherapy requires navigating distinct disease mechanisms, relapse patterns, and long-term immunosuppression hazards. While targeted drugs maintain clinical remission effectively, indefinite immunosuppression poses serious challenges like opportunistic infections, organ toxicity, and financial burden. Therefore, clinicians must carefully evaluate when therapeutic de-escalation is feasible and when maintenance therapy remains mandatory. Understanding these disease-specific differences ensures durable protection against severe neurodisability.

AQP4-Ab NMOSD: Why Maintenance Remains Indefinite

Aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder carries severe clinical consequences if left untreated. Consequently, experts strictly advise against complete therapy cessation in this patient group. Relapses in AQP4-Ab NMOSD are notoriously destructive, frequently causing cumulative visual loss and motor impairment. Furthermore, observational studies demonstrate that up to eighty percent of patients experience disease reactivation shortly after withdrawing immunosuppression. In contrast to other autoimmune conditions, even extended clinical remission does not eliminate relapse vulnerability. Nevertheless, selected stable patients may undergo careful dose de-escalation under close specialist supervision. Clinicians often lengthen dosing intervals for anti-CD20 monoclonal antibodies or cautiously reduce antimetabolite dosages. However, every tapering attempt demands intensive longitudinal vigilance. Healthcare providers must recognize that unmonitored drug cessation carries an unacceptable risk of irreversible disability. Thus, indefinite maintenance therapy remains the standard of care for virtually all seropositive patients.

MOGAD Management: Clinical Heterogeneity and Exit Strategies

Unlike classic neuromyelitis optica, myelin oligodendrocyte glycoprotein antibody-associated disease follows a distinctly heterogeneous clinical course. Pediatric patients frequently experience a monophasic illness with favorable visual and motor recovery. Moreover, epidemiological data indicate that adult relapse rates often decline significantly after the first few years of onset. Therefore, clinicians can consider de-escalation strategies more readily in this distinct demographic. Physicians regularly utilize extended interval dosing for rituximab or intravenous immunoglobulin after establishing initial disease stability. Furthermore, recent multicenter cohort studies confirm that complete treatment discontinuation is feasible in select individuals. Patients who sustain clinical remission for two to five years represent primary candidates for planned drug withdrawal. Additionally, loss of serum antibody positivity strongly reinforces the safety of tapering. Clinicians can safely discontinue maintenance therapy in persistently seronegative individuals while providing rapid access to rescue therapy if symptoms reappear.

Seronegative NMOSD: Navigating Diagnostic and Therapeutic Uncertainty

Double-seronegative neuromyelitis optica spectrum disorder presents unique diagnostic and therapeutic challenges for neurologists. Because targeted clinical trials specifically focused on seronegative cohorts are scarce, no approved biological agents exist for this subgroup. Nevertheless, acute inflammatory attacks can produce substantial permanent neurological disability. Consequently, clinicians rely primarily on broad-spectrum oral immunosuppressants or empiric monoclonal antibody regimens. Deciding whether to de-escalate treatment in seronegative patients requires extreme caution. Expert consensus suggests that clinicians may consider treatment cessation only after at least five consecutive years of proven stability. In addition, practitioners must repeat high-sensitivity live cell-based antibody testing before initiating any drug taper. False-negative initial testing during acute immunosuppression can obscure true serological status. Therefore, treatment withdrawal in seronegative disease remains guided strictly by personalized risk assessments and shared decision-making.

Indications for Tapering NMOSD and MOGAD Immunotherapy

Although disease control remains paramount, clinical reality frequently demands dose adjustments or therapy withdrawal. For instance, chronic immunosuppression substantially elevates the incidence of severe opportunistic infections and secondary malignancies. Furthermore, comorbidities such as chronic kidney disease, liver dysfunction, or leukopenia often necessitate immediate treatment modification. Treatment fatigue and severe financial toxicity also represent common real-world drivers of de-escalation. Additionally, pregnancy planning introduces critical management considerations for female patients of childbearing age. Neurologists must balance maternal disease stability against potential teratogenic risks and neonatal immunosuppression. For example, clinicians often switch teratogenic antimetabolites to safer alternatives like eculizumab, ravulizumab, or selected monoclonal antibodies before conception. Alternatively, physicians may carefully lengthen treatment intervals or defer infusions during specific trimesters. In all scenarios, proactive multidisciplinary coordination between neurologists and obstetricians remains vital.

Surveillance Protocols and Emerging Biomarkers

Safe treatment modification requires rigorous surveillance protocols to identify early subclinical disease activity. Consequently, regular magnetic resonance imaging of the brain, optic nerves, and spinal cord remains foundational. In addition, optical coherence tomography serves as a sensitive tool to quantify retinal nerve fiber layer thickness after optic neuritis attacks. Beyond imaging, researchers are actively investigating fluid biomarkers to guide therapeutic decisions. Specifically, elevated serum neurofilament light chain and glial fibrillary acidic protein levels signal active neuroaxonal damage and astrocytic injury. Although these biomarkers show tremendous promise for tracking subclinical inflammation, they are not yet fully standardized for daily clinical practice. Furthermore, longitudinal antibody titer monitoring provides crucial guidance in MOGAD cases. Future prospective randomized trials and international registry data will eventually establish precise, validated algorithms for safe treatment withdrawal.

Frequently Asked Questions

Can patients with AQP4-positive NMOSD safely discontinue immunotherapy?

No, clinicians should avoid discontinuing immunotherapy in AQP4-positive neuromyelitis optica spectrum disorder. Relapses in this condition are unpredictable, aggressive, and cause severe permanent disability. Observational studies demonstrate that over eighty percent of patients relapse after treatment cessation. Although careful dose de-escalation is possible in select individuals with prolonged remission, lifelong maintenance therapy remains the gold standard to prevent catastrophic attacks.

When can treatment discontinuation be considered in MOGAD?

Clinicians can consider discontinuing maintenance therapy in MOGAD after two to five years of sustained clinical remission. Candidates for withdrawal include patients who experience no new relapses and convert to seronegative status on cell-based assays. Because relapse risk naturally decreases over time, planned withdrawal is feasible under close clinical and radiological monitoring with prompt re-treatment protocols.

How should immunotherapy be managed during pregnancy in NMOSD and MOGAD?

Managing immunotherapy during pregnancy requires balancing maternal relapse prevention against fetal drug exposure. Physicians must discontinue teratogenic oral agents like methotrexate or mycophenolate mofetil before conception. In high-risk cases, clinicians often continue safe monoclonal antibodies or administer intravenous immunoglobulin. Individualized treatment plans and close collaborative monitoring between obstetricians and neurologists ensure optimal maternal-fetal outcomes.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Healthcare professionals should make clinical decisions based on their independent judgment and the individual circumstances of each patient. Refer to the latest local and national guidelines for clinical practice.

References

1. Hacohen Y et al. De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD. Neurology. 2026 Sep 22. doi: 10.1212/WNL.0000000000218482. PMID: 42647788.
2. Boudot de la Motte M, et al. Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. JAMA Neurol. 2026;83(5):512-520.
3. Kim SH, et al. Outcomes of Immunosuppressive Therapy Discontinuation in Patients With Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder. Mult Scler Relat Disord. 2021;56:103289.